[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:severe-aplastic-anemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":110,"states":111},"Severe Aplastic Anemia",16,13,[8,16,23,29,36,42,48,54,60,66,72,78,84,90,97,103],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03173937","Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.674573Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06517641","Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia",[20],"Phase 2","2026-08-26T02:18:58.958025Z","2026-05-05T02:43:29.495845Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04304820","Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)",[20],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:29.482342Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05757310","A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia",[33],"Phase 1","2026-08-26T02:15:51.395565Z","2026-05-05T02:43:27.994506Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06412497","MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.",[20],"2026-08-26T02:17:21.315591Z","2026-05-05T02:43:27.983701Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT01174108","Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells",[20],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:27.801814Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT03520647","Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis",[20],"2026-08-26T02:15:15.642947Z","2026-05-05T02:43:27.793861Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT02143830","HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy",[20],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:26.766237Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04356469","TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children",[20],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:29.170490Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT04099966","AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha\u002FBeta T Cell and CD19+ B Cell Depletion",[20],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:28.713058Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT03579875","Alpha\u002FBeta TCD HCT in Patients With Inherited BMF Disorders",[20],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.308563Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07145411","HPC Offered for PRESERVE Expansion",[],"2026-08-26T02:18:27.904411Z","2026-05-13T02:55:06.658697Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT01351545","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)",[],"2026-08-26T02:19:18.331180Z","2026-05-13T02:55:06.072349Z",{"nct_id":91,"title":92,"phases":93,"status":94,"updated_at":95,"content_modified":96},"NCT07712562","A Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes",[12],"NOT_YET_RECRUITING","2026-08-26T02:15:03.757872Z","2026-07-30T01:46:14.436804Z",{"nct_id":98,"title":99,"phases":100,"status":94,"updated_at":101,"content_modified":102},"NCT07381205","Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)",[],"2026-08-26T02:17:44.240289Z","2026-05-13T02:55:06.700451Z",{"nct_id":104,"title":105,"phases":106,"status":107,"updated_at":108,"content_modified":109},"NCT05998408","JAK1\u002F2 Inhibitor Ruxolitinib for Relapsed\u002FRefractory Immune Bone Marrow Failure",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:04:34.624671Z","2026-05-05T02:35:31.872333Z",[],[112,116,120,123,127,130,133,136,139,143,146],{"state":113,"count":114,"slug":115},"Maryland",7,"maryland",{"state":117,"count":118,"slug":119},"New York",5,"new-york",{"state":121,"count":118,"slug":122},"Ohio","ohio",{"state":124,"count":125,"slug":126},"Alabama",4,"alabama",{"state":128,"count":125,"slug":129},"California","california",{"state":131,"count":125,"slug":132},"Florida","florida",{"state":134,"count":125,"slug":135},"Minnesota","minnesota",{"state":137,"count":125,"slug":138},"Washington","washington",{"state":140,"count":141,"slug":142},"Georgia",3,"georgia",{"state":144,"count":141,"slug":145},"Michigan","michigan",{"state":147,"count":141,"slug":148},"Tennessee","tennessee"]